SI3254675T1 - Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem - Google Patents

Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem

Info

Publication number: SI3254675T1
Authority: SI; Slovenia
Prior art keywords: oral dosage; delayed release; dosage compositions; contain amorphous; cddo
Prior art date: 2009-02-13

Application number

SI201031906T

Other languages

English (en)

Inventor

Jiang Zhang

Colin J. Meyer

Original Assignee

Reata Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-13

Filing date

2010-02-12

Publication date

2019-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3254675(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-12 Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.

2019-08-30 Publication of SI3254675T1 publication Critical patent/SI3254675T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SI201031906T 2009-02-13 2010-02-12 Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem SI3254675T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15260809P	2009-02-13	2009-02-13
EP17181174.8A EP3254675B1 (en)	2009-02-13	2010-02-12	Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (1)

Publication Number	Publication Date
SI3254675T1 true SI3254675T1 (sl)	2019-08-30

Family

ID=42335073

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201031570T SI2395979T1 (sl)	2009-02-13	2010-02-12	Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem
SI201031906T SI3254675T1 (sl)	2009-02-13	2010-02-12	Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201031570T SI2395979T1 (sl)	2009-02-13	2010-02-12	Peroralni farmacevtski sestavki, ki vsebujejo amorfni CDDO-Me, z zapoznelim sproščanjem

Country Status (30)

Country	Link
US (2)	US8747901B2 (sl)
EP (2)	EP2395979B1 (sl)
JP (1)	JP5775464B2 (sl)
KR (2)	KR101483203B1 (sl)
CN (2)	CN105232471A (sl)
AU (1)	AU2010213594B2 (sl)
BR (1)	BRPI1008023B8 (sl)
CA (1)	CA2752048C (sl)
CO (1)	CO6361904A2 (sl)
CY (2)	CY1119595T1 (sl)
DK (2)	DK2395979T3 (sl)
EA (1)	EA023652B1 (sl)
ES (2)	ES2646816T3 (sl)
HK (1)	HK1220130A1 (sl)
HR (2)	HRP20171639T1 (sl)
HU (2)	HUE035013T2 (sl)
IL (1)	IL214258A (sl)
LT (2)	LT2395979T (sl)
MX (1)	MX2011008344A (sl)
MY (1)	MY173715A (sl)
NO (1)	NO2395979T3 (sl)
NZ (1)	NZ594488A (sl)
PL (2)	PL3254675T3 (sl)
PT (2)	PT2395979T (sl)
SG (1)	SG173601A1 (sl)
SI (2)	SI2395979T1 (sl)
SM (2)	SMT201900432T1 (sl)
TR (1)	TR201909743T4 (sl)
WO (1)	WO2010093944A2 (sl)
ZA (1)	ZA201105630B (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
CN104739841B (zh)	2008-01-11	2018-06-01	里亚塔医药公司	合成三萜类化合物及用以治病之方法
BRPI0911422B8 (pt)	2008-04-18	2021-05-25	Reata Pharmaceuticals Inc	compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
KR101665042B1 (ko)	2008-04-18	2016-10-11	리타 파마슈티컬스 잉크.	소염성 골격군을 포함하는 화합물 및 사용 방법
US8124799B2 (en)	2008-04-18	2012-02-28	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
EP2279197B1 (en)	2008-04-18	2014-11-05	Reata Pharmaceuticals, Inc.	Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
WO2010011782A1 (en)	2008-07-22	2010-01-28	Trustees Of Dartmouth College	Monocyclic cyanoenones and methods of use thereof
KR101483203B1 (ko)	2009-02-13	2015-01-15	리아타 파마슈티컬즈, 아이엔씨.	무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물
AU2011240690C1 (en)	2010-04-12	2014-11-06	Reata Pharmaceuticals Holdings, LLC	Method of treating obesity using antioxidant inflammation modulators
JP5857068B2 (ja)	2010-12-17	2016-02-10	リアタファーマシューティカルズインコーポレイテッド	抗酸化炎症モジュレーターとしてのピラゾリルおよびピリミジニル三環式エノン
TR201909788T4 (tr)	2011-03-11	2019-07-22	Reata Pharmaceuticals Inc	C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
CN103156861B (zh) *	2011-12-08	2015-11-25	陈丽梅	齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US9504679B2 (en)	2011-12-19	2016-11-29	Bjoern Colin Kahrs	Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en)	2011-12-19	2013-06-20	Ares Trading S.A.	Pharmaceutical compositions
DK2841445T3 (en)	2012-04-27	2017-09-11	Reata Pharmaceuticals Inc	2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONMETHYL, POLYMORPHE FORMS THEREOF AND PROCEDURES FOR USING IT
US8981144B2 (en)	2012-05-08	2015-03-17	Trustees Of Dartmouth College	Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en)	2012-05-08	2014-12-30	Trustees Of Dartmouth College	Triterpenoids and compositions containing the same
US9556222B2 (en)	2012-06-15	2017-01-31	Reata Pharmaceuticals, Inc.	A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en)	2012-09-10	2016-12-06	Reata Pharmaceuticals, Inc.	C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
BR112015005168A2 (pt)	2012-09-10	2017-08-15	Reata Pharmaceuticals Inc	Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
WO2014040073A1 (en)	2012-09-10	2014-03-13	Reata Pharmaceuticals, Inc.	C13-hydroxy derivatives of oleanolic acid and methods of use thereof
AR096046A1 (es)	2013-04-24	2015-12-02	Abbvie Inc	Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
TWI716341B (zh)	2013-08-23	2021-01-21	美商瑞塔醫藥有限責任公司	使用齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅｍｅｔｈｙｌ）或其類似物治療和預防內皮功能障礙之方法
EP3212195A4 (en)	2014-10-31	2018-06-06	The Regents of The University of California	Compositions and methods for treating hiv-associated cognitive dysfunction
NZ734292A (en)	2015-02-12	2022-09-30	Reata Pharmaceuticals Inc	Imidazolyl tricyclic enones as antioxidant inflammation modulators
ES2865163T3 (es)	2015-09-23	2021-10-15	Reata Pharmaceuticals Inc	Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos
MA46749A (fr)	2016-11-08	2019-09-18	Reata Pharmaceuticals Inc	Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier
TWI831738B (zh)	2016-12-16	2024-02-11	美商瑞塔醫藥有限責任公司	用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en)	2017-07-13	2019-01-17	Pliva Hrvatska D.O.O.	NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
CN112004529B (zh)	2018-04-06	2023-08-08	比利时胶囊公司	包含聚[(甲基丙烯酸甲酯)-共-(甲基丙烯酸)]的低纵横比颗粒的喷雾干燥方法
JP7498122B2 (ja)	2018-06-15	2024-06-11	リアタファーマシューティカルズインコーポレイテッド	ＩＬ－１７およびＲＯＲγの阻害用のピラゾール化合物およびイミダゾール化合物
EP3810141A1 (en)	2018-06-20	2021-04-28	Reata Pharmaceuticals, Inc.	Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
KR20210096162A (ko)	2018-11-27	2021-08-04	쿄와 기린 가부시키가이샤	의약 조성물
US12344631B2 (en)	2019-07-19	2025-07-01	Reata Pharmaceuticals, Inc.	C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
IL298008A (en)	2020-05-09	2023-01-01	Reata Pharmaceuticals Holdings Llc	Methods for treating covid-19 with the help of bardoxolone methyl or its analogs
AU2021397631A1 (en)	2020-12-11	2023-07-20	Reata Pharmaceuticals Holdings, LLC	Synthetic triterpenoids for use in therapy
CN114558019A (zh) *	2022-03-26	2022-05-31	中国科学院昆明动物研究所	一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6326507B1 (en)	1998-06-19	2001-12-04	Trustees Of Dartmouth College	Therapeutic compounds and methods of use
US7435755B2 (en) *	2000-11-28	2008-10-14	The Trustees Of Dartmouth College	CDDO-compounds and combination therapies thereof
JP2008110962A (ja) *	2006-08-02	2008-05-15	Santen Pharmaceut Co Ltd	Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) *	2006-10-30	2009-08-19	ミツミ電機株式会社	カメラモジュール
JP2008247898A (ja) *	2007-03-08	2008-10-16	Santen Pharmaceut Co Ltd	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en)	2007-08-15	2012-01-03	Reata Pharmaceuticals Inc.	Forms of CDDO methyl ester
CN104739841B (zh) *	2008-01-11	2018-06-01	里亚塔医药公司	合成三萜类化合物及用以治病之方法
KR101483203B1 (ko)	2009-02-13	2015-01-15	리아타 파마슈티컬즈, 아이엔씨.	무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물

2010
- 2010-02-12 KR KR1020117021250A patent/KR101483203B1/ko active Active
- 2010-02-12 HU HUE10704298A patent/HUE035013T2/en unknown
- 2010-02-12 TR TR2019/09743T patent/TR201909743T4/tr unknown
- 2010-02-12 NO NO10704298A patent/NO2395979T3/no unknown
- 2010-02-12 PT PT107042988T patent/PT2395979T/pt unknown
- 2010-02-12 AU AU2010213594A patent/AU2010213594B2/en active Active
- 2010-02-12 SG SG2011057122A patent/SG173601A1/en unknown
- 2010-02-12 NZ NZ594488A patent/NZ594488A/xx unknown
- 2010-02-12 SI SI201031570T patent/SI2395979T1/sl unknown
- 2010-02-12 PT PT17181174T patent/PT3254675T/pt unknown
- 2010-02-12 DK DK10704298.8T patent/DK2395979T3/da active
- 2010-02-12 LT LTEP10704298.8T patent/LT2395979T/lt unknown
- 2010-02-12 DK DK17181174.8T patent/DK3254675T3/da active
- 2010-02-12 CN CN201510540397.8A patent/CN105232471A/zh active Pending
- 2010-02-12 SM SM20190432T patent/SMT201900432T1/it unknown
- 2010-02-12 CN CN201080007105XA patent/CN102387789A/zh active Pending
- 2010-02-12 CA CA2752048A patent/CA2752048C/en active Active
- 2010-02-12 SM SM20170527T patent/SMT201700527T1/it unknown
- 2010-02-12 KR KR1020147001850A patent/KR20140016441A/ko not_active Withdrawn
- 2010-02-12 HR HRP20171639TT patent/HRP20171639T1/hr unknown
- 2010-02-12 SI SI201031906T patent/SI3254675T1/sl unknown
- 2010-02-12 PL PL17181174T patent/PL3254675T3/pl unknown
- 2010-02-12 HU HUE17181174A patent/HUE044005T2/hu unknown
- 2010-02-12 ES ES10704298.8T patent/ES2646816T3/es active Active
- 2010-02-12 LT LTEP17181174.8T patent/LT3254675T/lt unknown
- 2010-02-12 MY MYPI2011003694A patent/MY173715A/en unknown
- 2010-02-12 MX MX2011008344A patent/MX2011008344A/es active IP Right Grant
- 2010-02-12 JP JP2011550279A patent/JP5775464B2/ja active Active
- 2010-02-12 BR BRPI1008023A patent/BRPI1008023B8/pt active IP Right Grant
- 2010-02-12 WO PCT/US2010/024127 patent/WO2010093944A2/en not_active Ceased
- 2010-02-12 PL PL10704298T patent/PL2395979T3/pl unknown
- 2010-02-12 ES ES17181174T patent/ES2731601T3/es active Active
- 2010-02-12 EA EA201190092A patent/EA023652B1/ru not_active IP Right Cessation
- 2010-02-12 EP EP10704298.8A patent/EP2395979B1/en active Active
- 2010-02-12 EP EP17181174.8A patent/EP3254675B1/en active Active
- 2010-02-12 US US13/201,398 patent/US8747901B2/en active Active
2011
- 2011-07-24 IL IL214258A patent/IL214258A/en active IP Right Grant
- 2011-07-29 ZA ZA2011/05630A patent/ZA201105630B/en unknown
- 2011-08-09 CO CO11100847A patent/CO6361904A2/es not_active Application Discontinuation
2014
- 2014-04-30 US US14/266,031 patent/US9155721B2/en active Active
2016
- 2016-07-13 HK HK16108241.2A patent/HK1220130A1/zh unknown
2017
- 2017-11-13 CY CY20171101183T patent/CY1119595T1/el unknown
2019
- 2019-06-17 HR HRP20191092 patent/HRP20191092T1/hr unknown
- 2019-07-17 CY CY20191100761T patent/CY1122066T1/el unknown

Also Published As

Publication number	Publication date
HRP20171639T1 (hr)	2017-12-15
US20120022156A1 (en)	2012-01-26
KR101483203B1 (ko)	2015-01-15
SMT201700527T1 (it)	2018-01-11
SI2395979T1 (sl)	2017-12-29
ES2731601T3 (es)	2019-11-18
CY1119595T1 (el)	2018-03-07
EP3254675A1 (en)	2017-12-13
ZA201105630B (en)	2012-04-25
US20140235711A1 (en)	2014-08-21
EA023652B1 (ru)	2016-06-30
AU2010213594A1 (en)	2011-08-18
ES2646816T3 (es)	2017-12-18
MY173715A (en)	2020-02-18
KR20140016441A (ko)	2014-02-07
NZ594488A (en)	2013-10-25
LT2395979T (lt)	2017-12-11
IL214258A (en)	2017-06-29
EA201190092A1 (ru)	2012-02-28
JP2012518008A (ja)	2012-08-09
CO6361904A2 (es)	2012-01-20
LT3254675T (lt)	2019-06-25
JP5775464B2 (ja)	2015-09-09
BRPI1008023B1 (pt)	2019-12-31
PT3254675T (pt)	2019-06-14
EP2395979A2 (en)	2011-12-21
NO2395979T3 (sl)	2018-01-20
CA2752048A1 (en)	2010-08-19
HK1220130A1 (zh)	2017-04-28
SG173601A1 (en)	2011-09-29
WO2010093944A2 (en)	2010-08-19
BRPI1008023B8 (pt)	2023-04-11
CA2752048C (en)	2014-11-25
KR20110118721A (ko)	2011-10-31
HUE035013T2 (en)	2018-05-02
CY1122066T1 (el)	2020-11-25
PT2395979T (pt)	2017-11-16
SMT201900432T1 (it)	2019-09-09
CN105232471A (zh)	2016-01-13
MX2011008344A (es)	2011-09-29
US8747901B2 (en)	2014-06-10
CN102387789A (zh)	2012-03-21
PL2395979T3 (pl)	2018-02-28
PL3254675T3 (pl)	2019-09-30
EP2395979B1 (en)	2017-08-23
WO2010093944A3 (en)	2011-08-11
AU2010213594B2 (en)	2013-11-14
US9155721B2 (en)	2015-10-13
DK3254675T3 (da)	2019-06-24
IL214258A0 (en)	2011-09-27
DK2395979T3 (da)	2017-11-27
TR201909743T4 (tr)	2019-07-22
BRPI1008023A2 (pt)	2016-03-15
HRP20191092T1 (hr)	2019-11-29
EP3254675B1 (en)	2019-05-15
HUE044005T2 (hu)	2019-09-30

Publication	Publication Date	Title
IL214258A0 (en)	2011-09-27	Delayed release, oral dosage compositions that contain amorphous cddo-me
ZA201400310B (en)	2015-12-23	Solid dosage form
GB0909680D0 (en)	2009-07-22	Dosage form
IL218928A (en)	2016-10-31	Corticosteroids for oral administration
ZA201109176B (en)	2013-02-27	Homeglobin compositions
IL217949A0 (en)	2012-03-29	Pesticdal compositions
IL222353A0 (en)	2012-12-31	Very low-dosed solid oral dosage forms for hrt
GB0906515D0 (en)	2009-05-20	Fungical compositions
ZA201109312B (en)	2013-02-27	Compositions
EP2519290A4 (en)	2015-06-10	DENTAL SELF-MIXING PROCEDURES, DEVICES AND COMPOSITIONS
PL2226355T3 (pl)	2012-11-30	Kompozycje poliolefinowe sieciowane wilgocią
EP2437733A4 (en)	2014-01-08	RETARD-PHARMACEUTICAL FORM
IL214127A0 (en)	2011-08-31	Vaccine compositions
IL220308A0 (en)	2012-07-31	Vaccine compositions
GB0905165D0 (en)	2009-05-06	Compositions
ZA201304087B (en)	2016-01-27	Oral compositions
ZA201207441B (en)	2013-06-26	Amorphous roxithromycin composition
GB0822124D0 (en)	2009-01-07	Oral dosage form
ZA201109084B (en)	2012-08-29	Burst drug release compositions
ZA201107848B (en)	2014-03-26	Oral composition
IL218947A0 (en)	2012-07-31	Delayed release compositions
GB0908963D0 (en)	2009-07-01	Compositions
GB0900544D0 (en)	2009-02-11	Oral hygiene compositions
GB201000722D0 (en)	2010-03-03	Oral hygiene compositions
TWM369933U (en)	2009-12-01	Porcelain package structure